AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
-
Fusion Antibodies PLC reports significant revenue growth, with expected first-half revenues reaching £1.2 million, more than double the previous year’s figure.
-
The company achieves a notable improvement in gross margin, rising to 29% compared to -16% in the prior year.
-
Expansion of collaborations and new contracts, including a partnership with the National Cancer Institute, enhances the company’s growth prospects.
Fusion Antibodies PLC {LSE:FAB} has seen a 4% increase in its share price during early trading following the announcement of positive financial progress ahead of its annual meeting. The life sciences group anticipates first-half revenues to reach £1.2 million, more than doubling the £541,000 recorded in the same period last year. This substantial growth in revenue reflects the company's ongoing operational enhancements and strategic initiatives.
In addition to the revenue growth, Fusion Antibodies has significantly improved its gross margin, which has risen to 29% compared to a negative 16% margin reported in the previous year. This turnaround in financial performance highlights the effectiveness of the company’s strategies to enhance profitability and operational efficiency.
The company has also expanded its collaborations, notably with the National Cancer Institute, and has secured new contracts that include the development of an antibody therapeutic in partnership with a U.S. biotech firm. These collaborations not only enhance Fusion Antibodies’ portfolio but also position it for future growth in the competitive life sciences sector.
Furthermore, Fusion Antibodies reported that it has a cash runway extending into the second half of the financial year 2026, indicating a solid financial position that supports ongoing operations and strategic initiatives. The company remains focused on achieving cash neutrality, which would further strengthen its financial stability.
Following these positive developments, the stock rose by 0.15p, bringing its current price to 4.2p. Overall, the announcements reflect Fusion Antibodies' commitment to growth and innovation within the life sciences industry, bolstered by strategic partnerships and improved financial metrics.